Methods: From July 2010-December 2011, we enrolled 787 GPs in 150 clinics (response rate >90%) in 54 towns. Chlamydia testing rates (the proportion who consult a GP and have a test during 12 months) and re-testing rates (proportion who are re-tested within 12 (±3) months following a negative or within 3 months following a positive test) were calculated.
Results: We analysed a total of 23,976 tests in intervention and 17,363 in control clinics. Prior to commencing the trial in 2010, chlamydia testing rates were 10.2% in intervention clinics and 8.4% in control clinics. In 2012, testing rates were highest in clinics with 18+ months intervention time at 26.8% in women, 15.1% in men and 22.5% overall, compared with a testing rate of 10.3% in control clinics (relative risk=2.1; 95%CI: 2.0, 2.2). In 2012, chlamydia test positivity was 7.6% in intervention clinics and 8.7% in control clinics (p<0.01). Re-testing following a positive diagnosis was similar between intervention and control clinics (36.4% versus 33.9%; p=0.17). Re-testing after a negative test was higher in intervention clinics, but only slightly (20.5% versus 19.1%l (p<0.01).
Conclusions: Testing rates are increasing in intervention clinics while remaining relatively constant in control clinics showing that a multifaceted intervention in general practice can increase chlamydia testing rates over time. Further efforts are needed to increase re-testing after a positive and a negative test.
The case is of a 30 year-old HIV positive Zimbabwean woman (UK resident) who arrived in Australia in January 2011 on a one-year working visa. She was diagnosed with HIV in 2003 in the UK and commenced on Atripla® in 2005. She was first seen in Adelaide in May 2011, requesting a script for Atripla.®.
Background: Liquid based anal Papanicolaou smears, followed by High Resolution Anoscopy (HRA) guided biopsies are increasingly being advocated to identify areas of High Grade Anal Intraepithelial Neoplasia (HGAIN). We hypothesized that the ability to identify HGAIN would increase with experience of the anoscopist, and that comparison with contemporary Papanicolaou smears might yield insights into technical abilities.
Indigenous Australians experience a greater burden of sexually transmitted infections, however are less likely than the general population to access sexual health services. We examined the effectiveness of an Indigenous cultural appropriateness audit in assessing a sexual health clinic with low rates of Indigenous clients.
Despite the high proportion of young people annually accessing general practices, including Aboriginal Medical Services (AMS), testing for Chlamydia trachomatis remains relatively low in urban areas. A project officer was employed within the Institute of Urban Indigenous Health (IUIH) to serve a mentoring and facilitation role for the SE Queensland network of AMS and their sexual health workers, with a view to improving testing, management and follow-up of chlamydia and other STIs by community controlled medical services.
Monocytes are a heterogeneous cell population having specialised functions and differing phenotype. They are a link between innate immune system and adaptive immune system therefore, to identify if immune activation exists in HIV-1 individuals with controlled virema and recovered CD4 T cell counts, we assessed cell surface monocyte activation markers (MAM) within the monocyte subsets.
Involving consumers in healthcare decisions is important for high quality care. We previously tested a brief, consumer-led intervention consisting of three questions in a trial employing trained, standardized patients. The intervention enhanced discussion of evidence and increased patient involvement. We now report a research translation study which tested implementation with real patients at a reproductive and sexual health clinic.
This presentation, "Responding to the needs of consumers with complex trauma histories a consumer perspective" focuses on the needs of adult survivors of child abuse, highlighting the frequent